Asia Pacific Viral Vector Market Size, Share, and COVID-19 Impact Analysis, By Vector Type (Adeno Associated Virus, Lentivirus, Retrovirus, Adeno Virus and Others), By Application (Cell & Gene Therapy, Vaccine, and Biopharmaceutical & Pharmaceutical Discovery), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, CROs and CMOs), and Asia Pacific Viral Vector Market Insights, Industry Trends, Forecast to 2035

Asia Pacific Viral Vector Market Insights Forecasts to 2035

• The Asia Pacific Viral Vector Market Size Was Estimated at USD 754.56 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 12.9% from 2025 to 2035
• The Asia Pacific Viral Vector Market Size is Expected to Reach USD 2867.45 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Asia Pacific Viral Vector Market Size is Anticipated to reach USD 2867.45 Million by 2035, Growing at a CAGR of 12.9% from 2025 to 2035. The market is driven by the rising demand for gene therapy, vaccines, and other innovative therapeutics to tackle the growing burden of genetic disorders, chronic diseases, and infectious diseases, among others.

Market Overview

Viral vectors represent a method to penetrate cells and deposit the genetic material. The procedure can be done either in living organisms or in vitro. Viruses in nature have mastered certain molecular mechanisms to efficiently deliver their genomic material to the host cells they infect. It is considered a method for curing monogenic diseases and rare genetic disorders by introducing or adding functional genes to replace malfunctioning ones. It plays a part in at least two treatments: CAR-T cell therapy and oncolytic viruses' treatments, the latter being periodically employed to either kill tumor cells or reinforce the immune system's ability to identify them as being tumors. Viral vectors are paramount in functional genomics, CRISPR/Cas9 delivery for gene editing, and tracing of cell lineages in developmental biology. The largest increase in area for AAV gene therapy was rare and super-rare diseases that were treated only with AAV or had no treatment at all. The viral vector manufacturing market in the Asia Pacific region is expected to grow throughout the forecast period. The larger investment in the biotech industry is expected to have a positive impact on the market growth.

Report Coverage

This research report categorizes the market for the Asia Pacific viral vector market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific viral vector market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific viral vector market.

Driving Factors

The viral vector market in Asia Pacific is driven by the growing prevalence of chronic conditions, and the heights of the regulatory approvals of vector-based therapies, and the demand for the production of viral vectors is going up. In November of the year 2023, Genezen, a U.S.-based contract development and manufacturing organization (CDMO), obtained financing of USD 18.5 million led by Ampersand Capital Partners to reinforce its growth path in the production of viral vectors and also providing better assistance to the innovators of cell and gene therapies.

Restraining Factors

The viral vector market in Asia Pacific is restrained by the manufacturing and cost barriers in viral vector research and production, and the high price associated with the production of viral vectors. Notwithstanding the great increase in demand, the market for AAV gene therapies is still hindered by the very difficult and expensive vector production process.

Market Segmentation

The Asia Pacific viral vector market share is categorised into vector type, application and end user.

• The adeno associated virus segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Asia Pacific viral vector market is segmented by vector type into adeno associated virus, lentivirus, retrovirus, adeno virus and others. Among these, the adeno associated virus segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The adeno-associated virus was the dominant sector in terms of revenue share, accounting for 47.55% of the total market in 2023. The adeno-associated virus (AAV) gene therapy market is on the threshold of a major growth transformation due to the increasing demand for gene delivery technologies that are safer, more stable, and more efficient. AAV vectors have been the choice of many gene therapy trials due to they provide a robust mix of safety, targeting, and longevity of gene expression.

• The cell & gene therapy segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on application, the Asia Pacific viral vector market is segmented into cell & gene therapy, vaccine, and biopharmaceutical & pharmaceutical discovery. Among these, the cell & gene therapy segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The growth of the segment is driven by the escalating occurrence of hereditary diseases and the corresponding rise of gene therapy methods. The progress made in viral vector technologies, particularly with adeno-associated viruses (AAVs), has contributed to the betterment of gene transfer regarding safety and efficiency. Moreover, the growing R&D expenditure and supportive regulatory clearances have sped up the process of developing and marketing gene therapies.

• The pharmaceutical and biotechnology companies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Asia Pacific viral vector market is segmented by end user into pharmaceutical and biotechnology companies, academic and research institutes, CROs and CMOs. Among these, the pharmaceutical and biotechnology companies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by the requirements are increasing requirements for gene and cell therapies, mainly in the fields of cancer and rare genetic diseases. Such organisations made considerable investments not only for R&D but also for the expansion of manufacturing capabilities in-house, to support both clinical and commercial production. Their presence was enhanced by the strategic partnerships and takeovers, whereas the approvals of viral vector-based therapies by regulatory bodies played a role, too.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific viral vector market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                                                                                                           

• Regenxbio Inc
• Oxford Biomedical Research
• Biogen Inc
• Thermo Fisher Scientific Inc
• Vector Builder
• AGC Biologics
• Origene Technologies
• Genezen laboratories
• Aldevron
• Vector Biosystems
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific viral vector market based on the below-mentioned segments:

Asia Pacific Viral Vector Market, By Vector Type

• Adeno Associated Virus
• Lentivirus
• Retrovirus
• Adeno Virus and Others

Asia Pacific Viral Vector Market, By Application

• Cell & Gene Therapy
• Vaccine
• Biopharmaceutical & Pharmaceutical Discovery

Asia Pacific Viral Vector Market, By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• CROs and CMOs